Court Allowed Amgen Lawsuit to Proceed
The First Circuit Court of Appeals has permitted a new theory of liability in litigation concerning the migraine drug Aimovig.
Updated on Oct. 13, 2026 in Biotech
The First Circuit Court of Appeals ruled that a lawsuit against Amgen Inc. may move forward regarding the death of a 25-year-old man. The litigation, initiated by a mother in Massachusetts, concerns the patient's use of the migraine medication Aimovig in 2018.
Why it matters
This appellate decision establishes a new legal pathway for plaintiffs challenging pharmaceutical manufacturers over post-market drug safety concerns. The case highlights the evolving standards for liability following the approval of new therapeutic treatments.
The ruling permits the pursuit of a specific legal theory against the manufacturer of Aimovig, a drug that was recently approved when the decedent consumed it in 2018.
The players
Amgen Inc.
A global biotechnology company focused on developing human therapeutics for serious illnesses, including Aimovig for migraine prevention.
First Circuit Court of Appeals
The federal appellate court that issued the ruling allowing the plaintiff's new legal theory to move forward.
The details
The First Circuit Court of Appeals issued a decision that allows a mother from Massachusetts to continue her case against Amgen Inc. The litigation focuses on the manufacturer's responsibility related to the tragic death of her 25-year-old son. The court’s action specifically validates a new theory of liability, enabling the plaintiff to proceed with arguments that were previously restricted or unaddressed in the case.
Timeline
The deceased man took the medication Aimovig in 2018.
The First Circuit Court of Appeals issued the ruling on October 13, 2026.
The Tech Race
This decision marks a potential departure from established precedents regarding the scope of liability for manufacturers of newly approved medications. It alters the regulatory risk landscape by permitting plaintiffs to test broader liability theories against established biotechnology firms.
This ruling primarily affects the legal strategies and liability exposures of pharmaceutical companies operating within Massachusetts and the broader jurisdiction. Patients and families involved in similar litigation may find new avenues to pursue claims, though the ultimate resolution of the case remains pending.
The takeaway
This appellate decision lowers the barrier for future lawsuits against drug manufacturers regarding post-approval safety concerns. Observers should track the progression of this case through the district court for future rulings on the merits of the newly permitted liability theory.
Further reading
For broader analysis on current legal and safety issues in the industry, visit the Biotech section.
Source note: This article includes information reported by Law360.
